Quarterly ResultMay 4, 2026, 05:08 PM
Evolus Q1 Net Loss Narrows to $10.67M; Revenue Up 6.7% to $73.14M
AI Summary
Evolus, Inc. reported a significant reduction in its net loss for the first quarter of 2026, narrowing to $10.67 million from $18.89 million in the prior year. Total net revenues increased by 6.7% to $73.14 million. The company also improved its loss from operations and reduced cash used in operating activities. Evolus secured a new $30 million revolving credit facility and terminated its At-the-Market Sales Agreement, having sold no shares. Milestone payments for Evolysse® products in Europe were triggered by October 2024 EU MDR approval, with payments due in October 2026 and December 2029.
Key Highlights
- Net loss narrowed to $10.67 million in Q1 2026 from $18.89 million in Q1 2025.
- Total net revenues increased 6.7% to $73.14 million in Q1 2026 from $68.52 million.
- Loss from operations improved to $6.85 million in Q1 2026 from $15.17 million.
- Net cash used in operating activities decreased to $9.95 million from $15.63 million.
- Secured a new $30 million Revolving Credit Facility on March 3, 2026.
- Terminated At-the-Market Sales Agreement on May 1, 2026, with no shares sold.
- Milestone payments for Evolysse® Europe products triggered by October 2024 EU MDR approval.
- Cash and cash equivalents were $49.79 million as of March 31, 2026.
Price Impact
More from EOLS